

Is this the shape of trials networks to come? As more and more acronyms are added to the alphabet soup of mutations known to play a role in some lung cancers, a group of 14 European centres plus one from the US and one in China have clubbed together to accelerate progress in learning about which therapeutic strategies work best in which molecular subtypes.

What do you think?

- Does the future lie in running multiple clinical trials of around 50 patients from small well-defined molecular subsets?
- Could this template work in other cancers?

You can read the article [here](#) . Press the comment button at the end and share your views.